Oncology Institute Inc
TOI3.380USD
-0.010-0.29%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
329.79MCap. mercado
PérdidaP/E TTM
Más Datos de Oncology Institute Inc Compañía
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Información de Oncology Institute Inc
Símbolo de cotizaciónTOI
Nombre de la empresaOncology Institute Inc
Fecha de salida a bolsaMar 13, 2020
Director ejecutivoVirnich (Daniel)
Número de empleados825
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 13
Dirección18000 Studebaker Rd
CiudadCERRITOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal90703
Teléfono15627353226
Sitio Webhttps://theoncologyinstitute.com/
Símbolo de cotizaciónTOI
Fecha de salida a bolsaMar 13, 2020
Director ejecutivoVirnich (Daniel)
Ejecutivos de Oncology Institute Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
--
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Por negocioUSD
Nombre
Ganancia
Proporción
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
Estadísticas de accionistas
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
Otro
79.09%
Accionistas
Accionistas
Proporción
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
Otro
79.09%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
12.34%
Hedge Fund
11.00%
Investment Advisor/Hedge Fund
10.03%
Venture Capital
5.53%
Individual Investor
4.89%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
Otro
50.68%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
2023Q2
180
58.28M
81.90%
-25.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
M33 Growth LLC
8.52M
9.12%
-5.15M
-37.65%
Sep 04, 2025
The Vanguard Group, Inc.
4.28M
4.58%
+2.53M
+144.52%
Jun 30, 2025
OncologyCare Partners LLC
4.11M
4.4%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.2%
+2.74M
+1088.12%
Jun 30, 2025
CenterBook Partners LP
715.90K
0.77%
+715.90K
--
Jun 30, 2025
Balyasny Asset Management LP
2.52M
2.69%
+371.00K
+17.28%
Jun 30, 2025
Wexford Capital LP
1.12M
1.2%
+1.12M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
1.37%
+893.70K
+231.68%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
Proporción0.11%
iShares Micro-Cap ETF
Proporción0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.03%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Oncology Institute Inc?
Los cinco principales accionistas de Oncology Institute Inc son:
M33 Growth LLC posee 8.52M acciones, lo que representa el 9.12% del total de acciones.
The Vanguard Group, Inc. posee 4.28M acciones, lo que representa el 4.58% del total de acciones.
OncologyCare Partners LLC posee 4.11M acciones, lo que representa el 4.40% del total de acciones.
Deerfield Management Company, L.P. posee 3.36M acciones, lo que representa el 3.59% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 3.00M acciones, lo que representa el 3.20% del total de acciones.
M33 Growth LLC posee 8.52M acciones, lo que representa el 9.12% del total de acciones.
The Vanguard Group, Inc. posee 4.28M acciones, lo que representa el 4.58% del total de acciones.
OncologyCare Partners LLC posee 4.11M acciones, lo que representa el 4.40% del total de acciones.
Deerfield Management Company, L.P. posee 3.36M acciones, lo que representa el 3.59% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 3.00M acciones, lo que representa el 3.20% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Oncology Institute Inc?
Los tres principales tipos de accionista de Oncology Institute Inc son:
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC
¿Cuántas instituciones poseen acciones de Oncology Institute Inc (TOI)?
A fecha de 2025Q3, 145 instituciones poseen acciones de Oncology Institute Inc, con un valor de mercado combinado de aproximadamente 39.72M, lo que representa el 42.48% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -2.03%.
¿Cuál es la mayor fuente de ganancias de Oncology Institute Inc?
El FY2025Q2, el segmento empresarial Dispensary revenue generó la ganancia más alta para Oncology Institute Inc, ascendiendo a 62.57M y representando el 52.23% de la ganancia total.
